Serum peroxiredoxin 3 is reduced in genetic carriers of Parkinsons disease

Introduction Mutations in leucine rich repeat kinase 2 (LRRK2) are responsible for autosomal dominant Parkinson’s disease (PD). G2019S remains the most common mutation, but is rare in Asia, while LRRK2 Asian-specific variants are associated with increased risk of PD.1 LRRK2 interacts with human peroxiredoxin 3 (PRDX3),2 a mitochondrial member of the antioxidant family of thioredoxin (Trx) peroxidases, increasing its inhibition and leading to mitochondrial dysfunction and oxidative damage.2 Mutations in LRRK2 reduce peroxidase activity and increase neuronal cell death.2 Serum PRDX3 is a surrogate marker of peroxidase activity, with lower levels reflecting lower peroxidase activity, but peripheral PRDX3 levels in PD with and without LRRK2 mutations have not been investigated. We hypothesised that PRDX3 levels may discriminate PD LRRK2 mutation carriers (PD+LRRK2+) from LRRK non-mutation carriers (PD+LRRK2–). Methods Participants were prospectively recruited from the National Neuroscience Institute, Singapore...

Source: Journal of Neurology, Neurosurgery and Psychiatry - February 14, 2023 Category: Neurosurgery Authors: Ng, A. S., Tan, J., Ng, E., Tay, K. Y., Au, W. L., Tan, L. C., Tan, E. K. Tags: PostScript Source Type: research